SOCM
SR One Capital Management Portfolio holdings
AUM
$461M
This Quarter Return
+36.49%
1 Year Return
+23.25%
3 Year Return
+188.96%
5 Year Return
–
10 Year Return
–
AUM
$364M
AUM Growth
+$364M
(+53%)
Cap. Flow
+$40.3M
Cap. Flow
% of AUM
11.08%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
2
Reduced
1
Closed
–
Top Buys
| 1 |
CRISPR Therapeutics
CRSP
|
$71.5M |
| 2 |
Nkarta
NKTX
|
$21.6M |
| 3 |
Mineralys Therapeutics
MLYS
|
$2.87M |
Top Sells
| 1 |
Arcellx
ACLX
|
$55.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Arcellx
ACLX
$3.85B
| $163M | 44.83% |
2,346,630
-800,000
| -25% | -$55.6M |
|
|
2
CRISPR Therapeutics
CRSP
$4.71B
| $71.5M | 19.64% |
+1,048,951
| New | +$71.5M |
|
3
ARS Pharmaceuticals
SPRY
$1.15B
| $41M | 11.26% |
4,012,903
| – | – |
|
|
4
Nkarta
NKTX
$151M
| $36M | 9.9% |
3,333,333
+2,000,000
| +150% | +$21.6M |
|
5
Design Therapeutics
DSGN
$315M
| $26.3M | 7.22% |
6,526,476
| – | – |
|
|
6
Mineralys Therapeutics
MLYS
$1.03B
| $26M | 7.15% |
2,016,822
+222,222
| +12% | +$2.87M |
|